What is bioavailability? It is the share of a medication that becomes available to do its job, plus the speed at which it gets there. Swallowing 10 milligrams does not mean all 10 milligrams reach the bloodstream. Digestion, the gut wall and the liver may remove some along the way. An injection under the skin avoids those first barriers, though it still does not guarantee that every molecule arrives.

That is why the same ingredient can behave differently as a tablet, a shot or a dissolving product. Bioavailability belongs to the exact drug, formulation and route—not just to the name printed on the label.

What is bioavailability in plain English?

The official definition is a little more precise. Federal regulation 21 CFR 320.1 points to the definitions in 21 CFR 314.3, where bioavailability means the rate and extent to which an active ingredient, or the part that produces an effect, is absorbed and becomes available at its site of action. In ordinary words: how much gets where it needs to go, and how fast.

Researchers usually estimate it from blood samples taken over time. They plot concentration against time and calculate the area under the curve, or AUC—the total exposure represented by that plot. Peak concentration shows how high the level rises; time to peak shows how quickly it gets there. Together, those measurements describe more than a single percentage can.

Absolute bioavailability compares a route with intravenous delivery, which puts a medicine directly into circulation and serves as the 100% reference. Relative bioavailability compares one non-intravenous formulation with another. Neither number, by itself, says whether a drug is strong, safe or a good fit for a particular person.

Why peptide bioavailability depends on the route

Peptides are short chains of amino acids, the building blocks of proteins. When swallowed, many meet proteases—digestive enzymes that cut proteins apart—and then face a gut lining that large, water-friendly molecules cross poorly. A useful molecule can therefore have very low oral bioavailability without being weak. The delivery route is the problem.

Semaglutide makes the contrast easy to see; the oral semaglutide guide covers the tablet design in detail. The current Rybelsus label, revised January 2026, estimates about 0.4% to 1% absolute bioavailability for its original oral formulation. It is paired with SNAC, an absorption enhancer that helps the peptide cross the stomach lining. The current Wegovy label, revised June 2026, reports 89% after subcutaneous administration, meaning an injection under the skin. Those percentages describe different products and routes, not a contest between a “good” and a “bad” molecule.

A 2018 study found that SNAC creates a local protective environment around the tablet and lets semaglutide cross stomach cells near where the tablet dissolves (Buckley et al., Science Translational Medicine). In two later trials, food left little or no measurable exposure, while longer fasting after the tablet increased exposure (Bækdal et al., Diabetes Therapy, 2021). These are label facts and study observations, not dosing instructions.

As of September 18, 2026, the day this article was written, a September 1 Nature Reviews Materials perspective noted that only a few permeation enhancers have made it into marketed medicines, with SNAC as a leading example. The definition of bioavailability has not changed; the fresh point is that successful oral peptide delivery still depends on deliberate, formulation-specific engineering (Janjua et al., 2026).

Why an oral claim needs evidence for that exact product

A label that says “oral” or “sublingual” describes where a product starts. It does not show how much intact peptide reaches circulation. A capsule may survive the stomach but fail to cross the intestine. A dissolving tablet may release material in the mouth, yet much of it may be swallowed. Each formulation needs its own pharmacokinetic data—measurements of what the body does to the drug over time.

This is the central gap behind many oral peptide claims. The page on oral BPC-157 explains why animal gut studies do not establish human capsule absorption. Stability in digestive fluid is only one hurdle; crossing into blood is another. A milligram figure on a package measures what went into the product, not what reached the body.

Bioavailability is not potency or effectiveness

A high percentage can sound like a score. It is not. Bioavailability measures exposure. Potency describes how much drug is needed to produce a measured effect. Effectiveness asks what happened in people under real clinical conditions. A medication with low oral bioavailability may still provide a useful exposure if the formulation and studied amount account for that loss.

“Absorbed” and “active” are not synonyms either. A laboratory can detect a molecule or a fragment without showing that enough intact drug reached the site of action. The reverse matters too: a drug can leave the bloodstream while later biological signals continue. That is why half-life is a separate question. Half-life tells how long it takes a measured concentration to fall by half; bioavailability tells how much arrived and how quickly.

One more common mix-up is bioavailability versus bioequivalence. Bioequivalence asks whether two comparable products deliver the active ingredient at a sufficiently similar rate and extent under similar study conditions. It requires comparative data. Sharing an ingredient name, dosage form or printed strength does not establish it.

How bioavailability shows up in a peptide prescription

Route is part of the medication, not an afterthought. A prescriber may weigh whether the published evidence belongs to an injection, a swallowed tablet or a product designed to dissolve in the mouth. They also need to know whether the exact formulation was studied, because an enhancer, coating or other inactive ingredient can change absorption.

The same caution applies to compounded medications. Strengths, inactive ingredients and dosage forms can vary by prescription and pharmacy, so evidence for one formulation does not automatically transfer to another. The guide to sermorelin tablets shows why a convenient dosage form and measured systemic exposure are different claims.

A useful label or pharmacy record should make the route unambiguous. The clinician can then match that route against the evidence, medical history and other medications. Bioavailability does not make the decision, but it tells the clinician how much confidence to place in a route comparison.

Absorption is movement from the administration site into the body. First-pass metabolism is drug breakdown in the gut wall or liver before a swallowed dose reaches general circulation. Exposure is the amount of drug measured over time. Half-life is how long the measured concentration takes to fall by half. Bioequivalence is a comparison between products, while bioavailability describes the rate and extent of delivery for one product.

The practical question is simple: does evidence for this exact formulation and route show that a predictable amount reaches the body? At Promise, a licensed provider reviews every request and decides whether the requested treatment and route fit the patient's history; not everyone qualifies.